Human JMJD2B, also known as JHDM3B and KDM4B (GenBank Accession No. NM_015015), a.a. 2-500 with N-terminal GST-tag, MW=83 kDa, expressed in Sf9 cells using a Baculovirus expression system.

O94953

JHDM3B, KDM4B

0.32 pmole/min/µg

10 µl reaction mix containing assay buffer with 20 mM HEPES (pH 7.4), 50 mM NaCl, 1mM TCEP, 500 µM α-ketoglutarate, 25 µM iron, 2mM ascorbic acid, 0.01% Tween-20, 0.5 µM biotinylated peptide substrate, and JMJD2B (2 – 10ng) added to the wells. Add antibody against di-methylated K9 peptide. Incubate for 30 min, then Streptavidin-conjugated secondary antibody followed by Alpha Screening detection.

45 mM Tris-HCl, pH 8.0, 124 mM NaCl, 2.4 mm KCl, 10% glycerol, 18 mM glutathione, and 3 mM DTT.

Aqueous buffer solution

At least 6 months at –80°C. Avoid freeze/thaw cycles. Storing diluted enzyme is not recommended, if necessary, use carrier protein (BSA 0.1 – 0.5%).

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Fodor, B.D., et al. (2006). Genes Dev. 20(12): 1557–1562.
2. Beyer S., et al. (2008). J. Biol. Chem. 283(52):36542-52.

Application Reference(s):
1. Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox (2017)
2. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth (2013)

Avoid freeze/thaw cycles.

Demethylase

Recombinant Protein